---
schema_version: "secwatch.filing_event.v1"
accession: "0001651308-23-000170"
form_type: "8-K"
ticker: "ONC"
cik: "0001651308"
company_name: "BeOne Medicines Ltd."
filed_at: "2023-12-08T23:59:59+00:00"
generated_at: "2026-06-07T15:38:29.982970+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.1
calibrated_materiality_score: 0.1
confidence: "high"
source: SEC EDGAR
---

# BeiGene renews consulting agreement with co-founder Dr. Xiaodong Wang through Dec 2026

## Summary
- Dr. Wang will continue as Chairman of Scientific Advisory Board under same terms as prior agreement.
- Annual fixed consulting fee remains $100,000; additional compensation possible at Company's discretion.
- Agreement effective Jan 1, 2024 to Dec 31, 2026; cancellable by Company with 30 days' notice.
- Prior consulting agreement expired Dec 31, 2023; renewal ensures continuity of scientific advisory.

## SEC filing metadata
- accession: 0001651308-23-000170
- form_type: 8-K
- ticker: ONC
- cik: 0001651308
- company_name: BeOne Medicines Ltd.
- filed_at: 2023-12-08T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.1
- calibrated_materiality_score: 0.1
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1651308/000165130823000170/0001651308-23-000170-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1651308/000165130823000170/bgne-20231207.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001651308-23-000170
- JSON: https://secwatch.observer/filing/0001651308-23-000170.json
- Plain text: https://secwatch.observer/filing/0001651308-23-000170.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.